Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2019
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
U Dafni, O Michielin, S Martin Lluesma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2005
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
G Fountzilas, D Skarlos, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2019
Gender medicine and oncology: report and consensus of an ESMO workshop
A D Wagner, S Oertelt-Prigione, A Adjei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2004
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
G Fountzilas, H P Kalofonos, U Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S Peters, E Felip, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 10, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis
S Martín-Lluesma, U Dafni, K Vervita, et al.
ESMO Open
|
April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
B Gyawali, E G E de Vries, U Dafni, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 29, 2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
G Fountzilas, U Dafni, H Gogas, et al.
ESMO Open
|
December 20, 2021
Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies
A S Berghoff, C Sessa, J C-H Yang, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2019
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
U Dafni, O Michielin, S Martin Lluesma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2005
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
G Fountzilas, D Skarlos, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2019
Gender medicine and oncology: report and consensus of an ESMO workshop
A D Wagner, S Oertelt-Prigione, A Adjei, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2004
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
G Fountzilas, H P Kalofonos, U Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S Peters, E Felip, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 10, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis
S Martín-Lluesma, U Dafni, K Vervita, et al.
ESMO Open
|
April 22, 2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
B Gyawali, E G E de Vries, U Dafni, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 29, 2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
G Fountzilas, U Dafni, H Gogas, et al.
ESMO Open
|
December 20, 2021
Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies
A S Berghoff, C Sessa, J C-H Yang, et al.
Page
of 8